Sector Expert: Alexander Zukiwski
Dr. Alexander Zukiwski is responsible for leading the clinical development and regulatory affairs teams supporting Arno's current and future pipeline of innovative therapies, focused on the treatment of cancer. He has more than 20 years of experience in global oncology drug development. He has more than 15 years of experience in global oncology drug development, and has supported the clinical evaluation and registration of many successful therapeutic agents, including Taxotere, Xeloda, Procrit/Eprex, Velcade, Yondelis and Doxil. Dr. Zukiwski was most recently executive vice president, clinical research, and chief medical officer at MedImmune Inc., where the organization he led was responsible for developing and implementing MedImmune's clinical research, medical affairs and safety strategies. Prior to joining MedImmune, Dr. Zukiwski held medical affairs and clinical development positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development LLC (JJPRD), Centocor and Ortho Biotech, including serving as therapeutic area head for oncology and acting head of oncology research and development. Before joining Johnson & Johnson, Dr. Zukiwski held clinical oncology positions at Hoffmann-LaRoche, Glaxo Wellcome and Rhone-Poulenc Rorer. He received a bachelor's degree in pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary, and conducted post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas MD Anderson Cancer Center.
Cancers are generally treated by destruction of cancer cells. Infectious diseases are generally treated by destruction of invading pathogens. If infected host cells are viewed as viable biological targets, new paradigms for development of anti-infective agents become apparent. In this interview with The Life Sciences Report, Alexander Zukiwski MD, CEO and CMO of Arno Therapeutics Inc., describes how onapristone and AR-42 for cancers, and AR-12 as an anti-infective agent, are positioned to move through clinical trials and boost investors' portfolios.